We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your body to burn more fat instead and hang on to muscle. There’s also a ...
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.
New industry rules require visual size checks or GP medical records for online fat jab purchases. The updated guidelines ensure weight-loss jabs like ...